The use of Buserelin-depo in the treatment ofcombined pathology of reproductive organs

The article presents the current data on the use of gonadotropin-releasing hormone (GnRH) agonists in the therapy of combined proliferative diseases of reproductive organs. This pathology is detected in most cases in patients aged 40–45 years. The main clinical symptoms of proliferative diseases include pain and abnormal uterine bleeding. Timely diagnosis of proliferative nosologies is very challenging due to the variety of symptoms, conflicting theories of etiopathogenesis, and difficulties in differential diagnosis. GnRH agonists completely block the synthesis of sex hormones, marked antiproliferative and antiangiogenic effects; therefore, they are the first line therapy for combined proliferative diseases demonstrating high efficacy and relative safety. The analysis of the literature showed high efficacy of the Russian drug Buserelin-depo in the treatment of combined proliferative gynecologic diseases (it is administered 3.75 mg intramuscularly, once every 28 days, during 6 months of therapy and 3 months of preoperative preparation). The use of Buserelin-depo makes it possible to reduce the size of myomatous nodes by 52% of the original volume, to control pain syndrome and abnormal uterine bleeding, to reduce the risk of recurrence of hyperplastic processes of the endometrium, and to reduce the risk of intraoperative complications. This enables the clinicians to use it widely not only in the therapy of proliferative diseases, but also in the preparation of patients with uterine fibroids and endometriosis for surgical treatment and postoperative adjuvant therapy. Its use can significantly improve the quality of life of this cohort of patients, reduce the number of radical treatment methods and improve the outcomes of organ-preserving operations.

Conclusion: GnRH agonists are the first line therapy for combined proliferative pathology of reproductive organs due to their effect on all links of pathogenesis, demonstrating high efficacy and safety. The Bucerelin-depo medication is highly effective and affordable; it has a convenient scheme of administration, which ensures high adherence to treatment; the use of algorithms for complex management is interesting and promising.